NGM Biopharmaceuticals, Inc.: Series B $51M

Posted in I - Series B, Q - 1Q10, R - WEST, X - Diabetes, X - Metabolism, X - Obesity, XX - CA

NGM Biopharmaceuticals (San Francisco, CA) a preclinical-stage biopharmaceutical company focused on diabetes, obesity and muscle wasting, closed a $51M Series B financing. Participants include The Column Group, Tichenor Ventures, Prospect Venture Partners and Rho Ventures.

Mar

2010

ZafGen, Inc.: Series B $8.1M

Posted in I - Series B, Q - 1Q10, R - NORTH EAST, X - Obesity, XX - MA

ZafGen (Cambridge, MA) a clinical-stage company focused on small molecule therapeutics for the treatment of obesity, closed a $8.1M Series B financing, bringing the total round to $28M. Participants include Atlas Venture, Third Rock Ventures and GreatPoint Ventures.

Mar

2010

Rhythm Pharmaceuticals, Inc.: Series A $10M

Posted in I - Series A, Q - 1Q10, R - NORTH EAST, X - Diabetes, X - GI, X - Metabolism, X - Obesity, XX - MA

Rhythm Pharmaceuticals (Boston, MA) a clinical-stage biopharmaceutical company whose peptide therapeutic agonists are focused on metabolic disorders, closed a $10M Series A financing. Participants include MPM Capital and New Enterprise Associates.

May

2009

Elixir Pharmaceuticals, Inc.: Series D $12M

Posted in I - Series D, Q - 2Q09, R - NORTH EAST, X - Diabetes, X - Metabolism, X - Obesity, XX - MA

Elixir Pharmaceuticals (Cambridge, MA) a late-stage pharmaceutical company focused on the treatment of metabolic diseases such as diabetes and obesity, closed a $12M Series D financing. Participants include MPM Capital, Arch Venture Partners, Oxford Bioscience Partners, Omega Funds and Physic Ventures.

Jan

2009

7TM Pharma, A/S: Series E $15M

Posted in I - Series E, Q - 1Q09, R - INTERNATIONAL, X - Cardiology, X - Metabolism, X - Obesity

7TM Pharma (Denmark) a clinical-stage company focused on discovery and development of therapeutics for metabolic diseases including obesity and cardiovascular diseases, closed a $15M Series E financing. Participants include Novo, Alta Partners, LD Pensions, Index Ventures, Johnson & Johnson Development Corp, Sofinnova Capital, Lombard Odier Darier Hentsch & Cie, SR One, Global Life Science Ventures, [...]

Feb

2008

Escoublac, Inc.: Series A $6.7M

Posted in I - Series A, Q - 1Q08, R - NORTH EAST, X - Diabetes, X - Metabolism, X - Obesity

Escoublac (Cambridge, MA) the first occupant in Biogen Idec new Innovation Incubator is developing treatments for metabolic diseases, type II diabetes and obesity, closed a $6.7M Series A financing. Participants include Biogen Idec.

Feb

2008

Gelesis, Inc.: Series A $16.0M

Posted in I - Series A, Q - 1Q08, R - NORTH EAST, X - GI, X - Obesity

Gelsis (Boston, MA) is developing a breakthrough treatment for obesity and other gastrointestinal disorders has closed a $16M Series A. Participants include OrbiMed, Queensland BioCapital Funds, PureTech Ventures, Lansing Brown Investments and the Cape Family Fund.

to top of page...